# US 2025/0144204 A1 · Adjuvant composition and vaccine composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144204 A1
- Document ID: US20250144204A1
- Status: Published application
- Kind: A1
- Application number: 18/832,910
- Filed: 2023-01-10
- Published: 2025-05-08
- Earliest claimed: 2022-01-25
- Assignees: Shin Nippon Biomedical Laboratories, Ltd.
- Applicants: Shin Nippon Biomedical Laboratories, Ltd.
- Inventors: Shunji HARUTA
- Web page: https://patentgrep.com/patent/US20250144204A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/12: Antivirals
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/575: {humoral response}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An adjuvant composition, comprising a complex comprising an adjuvant and microparticles of a biodegradable polymer and/or cyclodextrin, wherein the adjuvant is incorporated into the microparticles of the biodegradable polymer and/or encapsulated in the cyclodextrin.

## Claims

### Claim 1

An adjuvant composition, comprising a complex comprising an adjuvant and microparticles of a biodegradable polymer and/or cyclodextrin,
wherein the adjuvant is incorporated into the microparticles of the biodegradable polymer and/or encapsulated in the cyclodextrin.

### Claim 2 (depends on 1)

The adjuvant composition according to claim 1, wherein the adjuvant comprises at least one selected from the group consisting of terpenoids and glycosphingolipids.

### Claim 3 (depends on 1)

The adjuvant composition according to claim 1, wherein an amount of the adjuvant is 0.1 to 40 mass % based on the complex.

### Claim 4 (depends on 2)

The adjuvant composition according to claim 2, wherein the terpenoid comprises at least one selected from the group consisting of retinoids and squalene.

### Claim 5 (depends on 2)

The adjuvant composition according to claim 2, wherein the glycosphingolipid comprises α-galactosylceramide.

### Claim 6 (depends on 1)

The adjuvant composition according to claim 1, wherein the biodegradable polymer comprises at least one selected from the group consisting of poly(lactic-co-glycolic acid), poly(lactic acid), and derivatives thereof.

### Claim 7 (depends on 6)

The adjuvant composition according to claim 6, wherein the derivative of the biodegradable polymer is a chitosan derivative, a polyethylene glycol derivative, a lysine-modified polyethylene glycol derivative, an arginine-modified polyethylene glycol derivative, or an amino group-modified polyethylene glycol derivative.

### Claim 8 (depends on 1)

The adjuvant composition according to claim 1, wherein at least one selected from the group consisting of chitosan, hexadecyltrimethylammonium, didodecyldimethylammonium, dimethyldioctadecylammonium, and salts thereof is further incorporated into the complex comprising the adjuvant and the microparticles of the biodegradable polymer.

### Claim 9 (depends on 1)

The adjuvant composition according to claim 1, wherein an average particle diameter of the complex comprising the adjuvant and the microparticles of the biodegradable polymer, is 5 to 800 nm.

### Claim 10 (depends on 1)

The adjuvant composition according to claim 1, wherein an average molecular weight of the biodegradable polymer is 5,000 to 100,000.

### Claim 11 (depends on 1)

The adjuvant composition according to claim 1, further comprising, in addition to the complex comprising the adjuvant and the microparticles of the biodegradable polymer, at least one selected from the group consisting of alum, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, and derivatives thereof.

### Claim 12 (depends on 1)

The adjuvant composition according to claim 1, wherein the cyclodextrin comprises at least one selected from the group consisting of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, and derivatives thereof.

### Claim 13 (depends on 12)

The adjuvant composition according to claim 12, wherein the derivative of the cyclodextrin is a methyl derivative, a dimethyl derivative, or a hydroxypropyl derivative.

### Claim 14 (depends on 1)

The adjuvant composition according to claim 1, further comprising at least one selected from the group consisting of crystalline cellulose, mannitol, trehalose, and sucrose.

### Claim 15 (depends on 1)

The adjuvant composition according to claim 1, which is in the form of a solid.

### Claim 16 (depends on 1)

The adjuvant composition according to claim 1, for use in injection administration or mucosal administration.

### Claim 17 (depends on 1)

A vaccine composition, comprising the adjuvant composition according to claim 1, and a vaccine.

### Claim 18 (depends on 17)

The vaccine composition according to claim 17, wherein the vaccine is a vaccine against influenza virus, coronavirus, RS virus, herpes virus, or papillomavirus.

### Claim 19

A method for producing an adjuvant composition, the method comprising incorporating an adjuvant into microparticles of a biodegradable polymer to form a complex.

### Claim 20

A method for producing an adjuvant composition, the method comprising encapsulating an adjuvant in a cyclodextrin to form a complex.
